Research performed in Inserm U1096 Unit, concerns the evaluation of the mechanisms and the treatment of cardiovascular diseases, and especially vascular protection and improvement of cardiac contractile function. This research is transversal, and performed both in experimental model and in human.
Regarding vascular research, our work mostly concerns the protection of vascular endothelial cells in the context of cardiovascular risk factors or cardiovascular diseases (hypertension, diabetes, myocardial infarction, heart failure etc. ). We also investigate new biotherapy approaches for stimulation of angiogenesis and vasculogenesis.
Regarding cardiac research, our work mostly concerns the improvement of noninvasive detection of cardiac contractile dysfunction, the search for new treatments of heart failure, the study of the links between oxidative stress and heart failure, as well as the clinical evaluation of percutaneous aortic valve replacement.
Main contributions
Role of cytochrome P450-derived hyperpolarizing factors (EDHF) in endothelium-dependent vasodilatation in human, and consequences of its pharmacological restoration in cardio-metabolic diseases
Endothelial protective effects and reduction of heart failure by tyrosine phosphatase 1B inhibition
Beneficial effects of pharmacological heart rate reduction in heart failure
Discovery and clinical evaluation of percutaneous aortic valve replacement
Treatment of heart failure by localized slow delivery of angiogenic growth factors
Latest publications
2016
Gueret A, Harouki N, Favre J, Galmiche G, Nicol L, Henry JP, Besnier M, Thuillez C, Richard V, Kolkhof P, Mulder P, Jaisser F and Ouvrard-Pascaud A. Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction.Hypertension2016, 67: 717-23. 26902493
Maupoint J, Besnier M, Gomez E, Bouhzam N, Henry JP, Boyer O, Nicol L, Mulder P, Martinet J and Richard V. Selective Vascular Endothelial Protection Reduces Cardiac Dysfunction in Chronic Heart Failure.Circ Heart Fail2016, 9: e002895. 27059805
Benhamou Y, Bellien J, Armengol G, Brakenhielm E, Adriouch S, Iacob M, Remy-Jouet I, Le Cam-Duchez V, Monteil C, Renet S, Jouen F, Drouot L, Menard JF, Borg JY, Thuillez C, Boyer O, Levesque H, Richard V and Joannidès R. Role of Toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome.Arthritis Rheumatol2014, 66: 3210-20. 25047402
Besnier M, Galaup A, Nicol L, Henry JP, Coquerel D, Gueret A, Mulder P, Brakenhielm E, Thuillez C, Germain S, Richard V and Ouvrard-Pascaud A. Enhanced angiogenesis and increased cardiac perfusion after myocardial infarction in protein tyrosine phosphatase 1B-deficient mice.FASEB J2014 24760754
Coquerel D, Neviere R, Delile E, Mulder P, Marechal X, Montaigne D, Renet S, Remy-Jouet I, Gomez E, Henry JP, do Rego JC, Richard V and Tamion F. Gene Deletion of Protein Tyrosine Phosphatase 1B Protects Against Sepsis-Induced Cardiovascular Dysfunction and Mortality.Arterioscler Thromb Vasc Biol2014 24578383
2012
Bellien J, Iacob M, Remy-Jouet I, Lucas D, Monteil C, Gutierrez L, Vendeville C, Dreano Y, Mercier A, Thuillez C and Joannides R. Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension.Circulation2012, 125: 1266-75. 22412088
En cliquant sur “Accepter”,
vous nous autorisez à stocker les cookies sur votre appareil, dans le
cadre de l'amélioration de la navigation, pour analyser les usages et
pour la mesure d'audience de ce site. Visiter nos mentions légales pour plus d'informations.